Compounds > adenosine diphosphate ribose

adenosine diphosphate ribose and bmn 673

adenosine diphosphate ribose has been researched along with bmn 673 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hirota, K; Ibrahim, MA; Masutani, M; Ooka, M; Sasanuma, H; Shimizu, N; Takeda, S; Tsuda, M; Yamada, K; Yamada, S	1

Other Studies

1 other study(ies) available for adenosine diphosphate ribose and bmn 673

Article	Year
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Genes to cells : devoted to molecular & cellular mechanisms, 2022, Volume: 27, Issue:5 Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide	2022

Article

Year

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.

Genes to cells : devoted to molecular & cellular mechanisms, 2022, Volume: 27, Issue:5

Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide

2022